Proceed to www.neurologix.net and browse through their latest statement re their first quarter financials. Phase two trials must be close with this announcement......

John Mordock, President and Chief Executive Officer of Neurologix, noted that these first quarter financial results were consistent with the Company's expectations. "In March, we received authorization from the U.S. Food and Drug Administration for our planned Phase 2 clinical trial in Parkinson's disease," said Mr. Mordock. "This represents the crossing of a major hurdle for the development of our gene transfer approach to the treatment of this disease. We have been contracting with clinical sites and reviewing prospective trial subjects for this study, and expect to begin enrolling patients during the second quarter.